Amidst the threat of growing resistance of superbugs to available antibiotics worldwide, a crisis which scientists have warned in foreboding terms could push the world back to the pre-antibiotic era where people died of simple infections, there appears to be a flicker of hope after all, following the discovery of a medicine by a team under the leadership of a Ghanaian pharmacist and researcher.

The drug, omadacycline, which is set to hit the world market soon, was invented by Prof. Kwasi Adomako Ohemeng and his team and it’s assigned the United States (US) patent number 7,056,902.

Omadacycline was unveiled in October during an international conference of experts in the field of infectious disease as one of 10 new antibiotics in the global pipeline for resistant infections.

According to experts, omadacycline is the first-in-class aminomethylcycline which can overcome two main ways of bacteria resistance to tetracyclines: ribosomal protection and efflux pump.

The medicine will be released by a US-based company, Paratek Pharmaceuticals, where Prof. Ohemeng had served as an Executive Director of Medicinal Chemistry, and would likely be approved by the US FDA for the treatment of community-acquired bacterial infections by 2018.

Prof. Ohemeng is the current Dean for the Central Univeristy’s School of Pharmacy. He graduated with a Bachelor of Pharmacy (B.Pharm.) Honours degree from the Kwame Nkrumah University of Science and Technology (KNUST) in 1978.

Source : Pharmaceutical Society of Ghana